Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ABBV

Abbvie Inc

254.76

Jul 06 • 04:00PM ET -6.31 (-2.42%)

Healthcare Drug Manufacturers - General USA Mega NYSE

Today, 5:30 PMAbbVie revises 2026 adjusted EPS guidance to $13.91–$14.11 after $291M Q2 in-process R&D expense in SEC filing

Peers: LLY MRK PFE JNJ BMY AZN NVS AMGN NVO GILD

| Held by: VTI VOO IVV SPY VTV XLV VIG VYM DGRO VHT

Scroll to Statements

Index	S&P 500
Market Cap	450.11B
Enterprise Value	513.62B
Income	3.60B
Sales	62.82B
Book/sh	-3.77
Cash/sh	5.32
Dividend Est.	6.84 (2.68%)
Dividend TTM	6.74 (2.65%)
Dividend Ex-Date	Jul 15, 2026
Dividend Gr. 3/5Y	5.21% 6.56%
Payout	281.66%
Employees	57000
IPO	Dec 10, 2012

P/E	125.65
Forward P/E	15.73
PEG	0.74
P/S	7.17
P/B	-
P/C	47.93
P/FCF	22.53
EV/EBITDA	17.59
EV/Sales	8.18
Quick Ratio	0.68
Current Ratio	0.80
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	2.03
EPS next Y	16.19
EPS next Q	3.76
EPS this Y	42.19%
EPS next Y	13.89%
EPS next 5Y	21.33%
EPS past 3/5Y	-29.11% -2.81%
Sales past 3/5Y	1.75% 5.95%
EPS Y/Y TTM	-13.63%
Sales Y/Y TTM	9.50%
EPS Q/Q	-46.38%
Sales Q/Q	12.43%
Earnings	Jul 31 BMO
EPS/Sales Surpr.	2.25% 1.93%

Insider Own	0.13%
Insider Trans	-2.14%
Inst Own	77.37%
Inst Trans	-0.23%
ROA	2.64%
ROE	15221.82%
ROIC	6.21%
Gross Margin	70.58%
Oper. Margin	33.58%
Profit Margin	5.72%
SMA20	8.32%
SMA50	15.96%
SMA200	14.65%
Trades

Shs Outstand	1.77B
Shs Float	1.76B
Short Float	1.33%
Short Ratio	3.30
Short Interest	23.45M
52W High	261.64 -2.63%
52W Low	184.63 37.98%
Volatility	2.78% 2.64%
ATR (14)	6.76
RSI (14)	68.88
Beta	0.28
Rel Volume	1.16
Avg Volume	7.10M
Volume	8,214,345

Perf Week	0.56%
Perf Month	17.33%
Perf Quarter	21.99%
Perf Half Y	11.50%
Perf YTD	11.50%
Perf Year	34.59%
Perf 3Y	85.62%
Perf 5Y	120.13%
Perf 10Y	302.02%
Recom	1.66
Target Price	258.56
Prev Close	261.07
Price	254.76
Change	-2.42%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-26	Upgrade	BofA Securities	Neutral → Buy	$234
Apr-21-26	Initiated	Canaccord Genuity	Buy	$262
Feb-25-26	Initiated	RBC Capital Mkts	Outperform	$260
Feb-20-26	Initiated	Barclays	Overweight	$275
Jan-08-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-07-26	Resumed	UBS	Neutral	$240
Dec-10-25	Upgrade	HSBC Securities	Hold → Buy	$265
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$280
Nov-04-25	Downgrade	DZ Bank	Buy → Hold	$237
Oct-14-25	Downgrade	Erste Group	Buy → Hold
Oct-01-25	Downgrade	HSBC Securities	Buy → Hold
Sep-17-25	Upgrade	Berenberg	Hold → Buy	$270
Aug-12-25	Resumed	Piper Sandler	Overweight	$231
Aug-07-25	Upgrade	Daiwa Securities	Neutral → Outperform	$214
May-14-25	Downgrade	Citigroup	Buy → Neutral	$205
Apr-22-25	Initiated	Cantor Fitzgerald	Overweight	$210
Dec-10-24	Resumed	BofA Securities	Neutral	$191
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral	$180
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform	$206
Nov-15-24	Initiated	Wolfe Research	Outperform	$205

Show Previous Ratings

Today 04:23PM	What Eli Lilly Stock Said When It Had Too Much Business (Trefis)
01:45PM	AbbVie Announces TEPKINLY (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma (PR Newswire)
Jul-02-26 01:29PM	JNJ Stock Management Sees A Breakout, The Market Sees A Standoff (Trefis)
05:29AM	Can pharma sustain its $2T trajectory? (Pharma Voice)
Jun-30-26 04:24PM	Why Is JNJ Stock Defying The Markets Daily Mood Swings? (Trefis)
04:10PM	Loading…
04:10PM	US House committee opens investigation into Merck, AbbVie China drug trials (Reuters)
12:19PM	Merck, AbbVie probed by US lawmakers over China clinical trials: report (Proactive)
08:55AM	Merck, AbbVie investigated over China military hospital drug trials (Quartz)
05:35AM	Genmab Shares Climb After Lymphoma Therapy Hits Goal in Trial (The Wall Street Journal)
Jun-29-26 04:15PM	AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (PR Newswire)
02:33PM	AbbVie Stock Rockets 17% With 5-Day Winning Streak (Trefis)
01:37PM	Should You Chase The Breakout In Eli Lilly Stock? (Trefis)
03:10AM	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults and Adolescents with Severe Alopecia Areata (PR Newswire)
03:00AM	AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo (PR Newswire)
Jun-26-26 04:50PM	SKYRIZI (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease (PR Newswire)
02:39PM	Loading…
02:39PM	Healthcare stocks have become a haven for investors ditching tech (MarketWatch)
01:49PM	Lilly, J&J and AbbVie Hit New Highs (GuruFocus.com)
12:03PM	AbbVie Stock's Growth Story Has One Question Mark (Trefis)
08:00AM	AbbVie to Host Second-Quarter 2026 Earnings Conference Call (PR Newswire)
Jun-24-26 03:32PM	The Number That Could Test AbbVie Stock (Trefis)
02:15PM	VERAXA Biotech Expands R&D Hub in Heidelberg as Programs Advance Towards Clinical Development (Exec Edge)
08:00AM	BOTOX Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026 (PR Newswire)
Jun-23-26 06:36PM	Thinking Thin Pays Off: Lilly To Dominate Pharma World By 2032 (MediaPost)
03:57PM	The $50B Plan Merck Stock Was Broadcasting (Trefis)
08:45AM	AbbVie Secures EU Approval for Skyrizi in Pediatric Plaque Psoriasis (ABBV) (InvestorsHub)
08:20AM	Should You Buy Or Sell AbbVie Stock At $230? (Trefis)
08:00AM	Allergan Aesthetics receives approval for Boey (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients (PR Newswire)
05:00AM	AbbVie Announces European Commission Approval of MAVIRET (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection (PR Newswire)
03:00AM	AbbVie Announces European Commission Approval of SKYRIZI (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis (PR Newswire)
Jun-22-26 11:04PM	Why Did INTC, KEEL, APGE Stocks Hit 52-Week Highs Today? (Stocktwits) +6.25%
04:08PM	Loading…
04:08PM	AbbVie Goes On The Offensive With $10.9 Billion Takeover (Investor's Business Daily)
03:47PM	Abbvie acquiring Apogee for $10.9B, Coca-Cola vs. IRS in appeals court (Yahoo Finance Video)
02:59PM	AbbVie's $10.9 Billion Apogee Deal Joins a $200 Billion Pharma Spree (GuruFocus.com)
11:40AM	Prolium Bioscience Sclerosis, Lupus Treatment Studies Advancing (Exec Edge)
11:33AM	AbbVie deepens immunology legacy in $10.9bn Apogee buyout (Pharmaceutical Technology)
11:12AM	AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug \| Stock Movers (Bloomberg)
10:46AM	Merck Stocks New Drugs Were Already Answering The Big Question (Trefis)
10:04AM	AbbVie to acquire Apogee Therapeutics in $10.9B deal (Proactive)
09:08AM	Apogee Therapeutics, BitFuFu rise premarket; AbbVie gains after deal (Investing.com)
09:08AM	Why AbbVie Is Spending $11 Billion to Buy Apogee Therapeutics (Barrons.com)
08:58AM	AbbVie Strikes $10.9 Billion Deal for Apogee to Strengthen Future Immunology Portfolio (ABBV) (InvestorsHub)
08:46AM	Dow Jones opens higher but Nasdaq flat as hawkish Fed still looms (Proactive)
08:32AM	AbbVie acquires Apogee Therapeutics for $10.9 billion (Quartz)
08:32AM	AbbVie is buying an eczema and asthma drug developer for nearly $11 billion (Quartz)
08:08AM	5 Things to Know Before the Stock Market Opens (Investopedia)
07:42AM	AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash (The Wall Street Journal)
07:06AM	Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion. (Barrons.com)
07:00AM	AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio (PR Newswire)
Jun-20-26 12:11PM	AbbVie would gain an experimental eczema drug by buying biotech: report (MarketWatch)
Jun-19-26 04:09PM	Stocks Stall as Iran Nuclear Talks Hit Early Snag: Markets Wrap (Bloomberg)
Jun-18-26 08:56PM	How One Partnership Profit Line Reframes The Regeneron Pharmaceuticals Stock Story (Trefis) +6.25%
04:57PM	What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine? (Trefis)
04:05PM	AbbVie Declares Quarterly Dividend (PR Newswire)
Jun-17-26 02:21PM	Eli Lilly Stock's Trillion-Dollar Question (Trefis)
01:08PM	The Number That Could Test Johnson & Johnson Stock (Trefis)
11:57AM	Everyone Is Watching Eli Lilly Stock's New Drugs. Here Is the Metric That Vanished (Trefis)
Jun-16-26 08:15AM	Fresh Off Its Nasdaq Debut, a Regenerative-Medicine Upstart Is Stacking Its Board With Big-Pharma Firepower (PR Newswire)
08:00AM	Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVEDERM for the Improvement of Neck Appearance (PR Newswire)
Jun-12-26 04:53PM	What Could Push JNJ Stock Higher From Here? (Trefis)
03:14PM	JNJ Raised the Bar: So Why Is the Stock Standing Still? (Trefis)
01:31PM	The Catch Hiding In Eli Lilly Stock's Growth Story (Trefis)
03:00AM	AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA/VENCLYXTO (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results (PR Newswire)
Jun-11-26 02:03PM	Why Did Wall Street Misprice JNJ Stock? (Trefis)
Jun-10-26 08:00AM	Allergan Aesthetics Releases 'The Aesthetics Evolution: What Consumers Really Want' Highlighting Consumer Motivations and Expectations in Aesthetics (PR Newswire)
Jun-08-26 03:49PM	Why Is Lilly Stock Growing Like A Silicon Valley Tech Darling? (Trefis)
09:07AM	Can MariTide Save Amgen Stock From Its Fading Blockbusters? (Trefis)
08:55AM	Is AbbVie Stock The Right Defensive Pick In This Volatile Market? (Trefis)
08:00AM	AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 (PR Newswire)
Jun-05-26 06:55PM	Is Amgen An Undervalued Stock Or Value Trap? (Trefis)
Jun-04-26 04:23PM	75% Upside For LLY Stock? (Trefis)
07:06AM	AbbVie receives EC approval for Aquipta to treat migraine (Pharmaceutical Business Review)
Jun-03-26 03:30AM	Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick. (Barrons.com)
03:15AM	Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors (TMX Newsfile)
Jun-02-26 08:00AM	AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference (PR Newswire)
04:00AM	AbbVie Announces European Commission Approval of AQUIPTA (atogepant) for the Acute Treatment of Migraine in Adults (PR Newswire)
Jun-01-26 09:04PM	Glenmark Pharmaceuticals Ltd (BOM:532296) Q4 2026 Earnings Call Highlights: Strong Revenue ... (GuruFocus.com)
12:41PM	ASCO26: Platinum-resistant ADC leader Elahere stumbles in platinum-sensitive disease (Pharmaceutical Technology)
May-29-26 08:00AM	AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia (PR Newswire)
06:17AM	Allogene CEO to step down; Agios drug fails key test (BioPharma Dive)
May-28-26 06:33PM	Akari Therapeutics Highlights 1st ASCO Abstract Acceptance (IPO-Edge.com)
12:53PM	VERAXA Biotech Secures $27.5M Financing, to Go Public Via SPAC (Exec Edge)
05:30AM	J&J Mastered Cancer Biotech Deals on the Cheap. Can It Stay on the Cutting Edge? (The Wall Street Journal)
May-27-26 06:18PM	U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options (PR Newswire)
04:26PM	ABBV Stock Gains On Winning FDA Approval For Rare Blood Cancer Drug (Stocktwits)
May-22-26 08:00AM	AbbVie Announces Positive CHMP Opinion for MAVIRET (glecaprevir/pibrentasvir) for the Treatment of Acute Hepatitis C Infection (PR Newswire)
May-21-26 06:46PM	AbbVie Announces New Data at ASCO 2026 Demonstrating Breadth and Momentum Across its Next-Generation Oncology Pipeline (PR Newswire)
04:10PM	Allergan Aesthetics Receives Positive CHMP Opinion for Boey (TrenibotulinumtoxinE) for the Temporary Improvement of Moderate to Severe Glabellar Lines in Adults (PR Newswire)
May-06-26 10:07AM	This Small Biotech - Taking On AbbVie, Novartis And Sanofi - Just Catapulted Into A Breakout (Investor's Business Daily)
08:26AM	DDW 2026: key readouts from the conference (Clinical Trials Arena)
08:00AM	AbbVie to Present at the Bank of America Securities Healthcare Conference (PR Newswire)
May-05-26 08:05AM	AbbVie Highlights New Long-Term Data Advancing Treatment Standards in Inflammatory Bowel Diseases (IBD) at 2026 Digestive Disease Week (PR Newswire)
May-01-26 05:01PM	Watch: Why Investors Are Still Worried About AbbVie (The Wall Street Journal)
Apr-30-26 03:00PM	AbbVie and adMare BioInnovations Announce RIME Therapeutics as AbbVie Biotech Innovators Award Recipient in Quebec (GlobeNewswire)
09:36AM	Meta downgraded, Qualcomm upgraded: Wall Street's top analyst calls (The Fly)
07:01AM	Siemens, Diageo, Oxbo and others open US facilities in April (Manufacturing Dive)
Apr-29-26 12:49PM	AbbVie Inc. Q1 2026 Earnings Call Summary (Moby)
11:33AM	AbbVie Raises 2026 Outlook To $14.28 As Q1 Earnings Beat Estimates (GuruFocus.com)
09:11AM	AbbVie beats Q1 2026 earnings, raises full-year forecast (Quartz)
09:11AM	AbbVie beat earnings expectations and raised its outlook as newer drugs offset Humira's decline (Quartz)
08:48AM	AbbVie Hikes Earnings Outlook As Immunology Duo Outperforms (Investor's Business Daily)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson's disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

CEO & Chairman of the BoardMr. Robert A. Michael C.P.A.

Executive VP & CFOMr. Scott T. Reents

Executive VP & COODr. Azita Saleki-Gerhardt Ph.D.

Executive VP of Research & Development and Chief Scientific OfficerDr. Roopal B. Thakkar M.D.

Executive VP & Chief Commercial OfficerMr. Jeffrey Ryan Stewart

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ROBERT J ALPERN	Director	May 26 '26	Proposed Sale	214.00	13,000	2,781,991		May 26 04:10 PM
Purdue David Ryan	SVP, Controller	Mar 04 '26	Sale	233.56	5,230	1,221,519	2,654	Mar 06 05:05 PM
David R. Purdue	Officer	Mar 04 '26	Proposed Sale	233.56	5,230	1,221,519		Mar 06 05:04 PM
Siatis Perry C	EVP, GC AND SECRETARY	Mar 02 '26	Sale	234.39	18,668	4,375,549	4,619	Mar 03 06:10 PM
PERRY C SIATIS	Officer	Mar 02 '26	Proposed Sale	234.39	18,668	4,375,585		Mar 02 04:05 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Option Exercise	172.62	22,381	3,863,458	60,518	Feb 27 05:00 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 25 '26	Sale	230.00	22,381	5,147,630	38,137	Feb 27 05:00 PM
PERRY C SIATIS	Officer	Feb 25 '26	Proposed Sale	230.00	22,381	5,147,630		Feb 25 04:49 PM
Richard A. Gonzalez	Former Director	Aug 22 '25	Proposed Sale	210.84	62,755	13,231,264		Aug 22 06:02 PM
Richard A. Gonzalez	Former Director	Aug 21 '25	Proposed Sale	211.04	90,000	18,993,948		Aug 21 06:04 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Option Exercise	54.86	42,370	2,324,418	219,662	Aug 14 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Aug 12 '25	Sale	198.42	42,370	8,407,055	177,292	Aug 14 05:00 PM
AZITA SALEKI-GERHARDT	Officer	Aug 12 '25	Proposed Sale	198.42	42,370	8,407,068		Aug 12 07:22 PM
Richard A. Gonzalez	Former Director	Aug 01 '25	Proposed Sale	195.83	61,500	12,043,268		Aug 08 05:03 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Aug 05 '25	Sale	198.51	13,295	2,639,253	58,247	Aug 07 05:00 PM
NICHOLAS DONOGHOE	Officer	Aug 05 '25	Proposed Sale	198.51	13,299	2,639,966		Aug 05 04:40 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your Finviz experience